1. Search Result
Search Result
Results for "

SARS-CoV-2 PLpro

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

2

Fluorescent Dye

2

Natural
Products

3

Recombinant Proteins

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100575
    Acriflavine
    5+ Cited Publications

    Acriflavinium chloride 3,6-Acridinediamine mix

    Environmental Pollutants Fluorescent Dye Monocarboxylate Transporter Bacterial Fungal HIF/HIF Prolyl-Hydroxylase SARS-CoV Infection Cancer
    Acriflavine (Acriflavinium chloride) is a fluorescent acridine dye that can be used to label nucleic acid. Acriflavine is an antiseptic agent. Acriflavine is a potent HIF-1 inhibitor that prevents the dimerization of HIF-1α and HIF-1β subunits. Acriflavine inhibits the interaction between monocarboxylate transporter 4 (MCT4) and Basigin. Acriflavine is used in cancer research, such as breast cancer, brain tumor and chronic myeloid leukemia. Acriflavine is a potent papain-like protease (PLpro) inhibitor, which inhibits SARS-CoV-2 .
    Acriflavine
  • HY-169092

    SARS-CoV Virus Protease Infection
    PF-07957472 (Compound 4) is an orally active and selective SARS-CoV-2 papain-like protease (PLpro) inhibitor, with a Ki of 2 nM against SARS-CoV-2 PLpro. PF-07957472 reduces SARS-CoV-2 viral titers in the lungs of infected mice and inhibits SARS-CoV-2-induced cytopathic effects in cells. PF-07957472 can be used for the research of COVID-19 .
    PF-07957472
  • HY-W088075
    Acriflavine hydrochloride
    Maximum Cited Publications
    7 Publications Verification

    Acriflavinium chloride hydrochloride

    Fluorescent Dye HIF/HIF Prolyl-Hydroxylase Bacterial SARS-CoV Monocarboxylate Transporter Fungal Infection Cancer
    Acriflavine (Acriflavinium chloride) hydrochloride is a fluorescent acridine dye that can be used to label nucleic acid. Acriflavine hydrochloride is an antiseptic agent. Acriflavine hydrochloride is a potent HIF-1 inhibitor that prevents the dimerization of HIF-1α and HIF-1β subunits. Acriflavine hydrochloride inhibits the interaction between monocarboxylate transporter 4 (MCT4) and Basigin. Acriflavine hydrochloride is used in cancer research, such as breast cancer, brain tumor and chronic myeloid leukemia. Acriflavine hydrochloride is a potent papain-like protease (PLpro) inhibitor, which inhibits SARS-CoV-2 .
    Acriflavine hydrochloride
  • HY-N0886
    Aloin B
    3 Publications Verification

    Isobarbaloin

    SARS-CoV Virus Protease Infection Endocrinology Cancer
    Aloin B (Isobarbaloin) is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor with an IC50 of 16.08 μM (hydrolytic activity) and 17.51 μM (deubiquitinase activity). Aloin B is metabolized by rat intestinal flora into aloe-emodin-9-anthrone to exert laxative effects. Aloin B inhibits TPA (HY-18739)-induced ear edema, putrescine elevation, and tumor promotion in mouse skin. Aloin B can be used in research related to anti-inflammation, tumor promotion inhibition, coronavirus disease 2019 (COVID-19) and constipation .
    Aloin B
  • HY-17542
    PLpro inhibitor
    5 Publications Verification

    SARS-CoV Infection
    PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with an IC50 of 2.6 µM . PLpro inhibitor inhibits SARS-CoV-2 PLpro with an IC50 of 5.0 µM and an EC50 of 21.0 µM .
    PLpro inhibitor
  • HY-152101

    SARS-CoV Infection
    LY1 is a potent, selective and covalent inhibitor against both SARS-CoV-2 PL pro and M pro with Kd values of 1.5 μM and 2.3 μM for M pro C145A protein and PL pro C111A protein, respectively. LY1 potent against the viral proteases, with IC50s of 0.12 μM and 0.99 μM against M pro and PL pro. LY1 shows high selectivity over other kinases, human proteases and metalloenzyme .
    LY1
  • HY-178160

    SARS-CoV Virus Protease Infection
    SARS-CoV-2 PLpro-IN-2 (Compound 12) is a highly selective SARS-CoV-2 papain-like protease (PLpro) inhibitor of (IC50=0.06 μM). SARS-CoV-2 PLpro-IN-2 inhibits viral replication and immune evasion. SARS-CoV-2 PLpro-IN-2 exhibits antiviral efficacy in HeLa-ACE2 cells (EC50=2.9 μM). SARS-CoV-2 PLpro-IN-2 is promising for research of COVID-19 .
    SARS-CoV-2 PLpro-IN-2
  • HY-181927

    SARS-CoV Virus Protease Infection
    SARS-CoV-2 PLpro-IN-7 (Compound 18) is a selective SARS-CoV-2 PLpro inhibitor with an IC50 of 13.3 μM. SARS-CoV-2 PLpro-IN-7 exerts antiviral activity against SARS-CoV-2 (with an EC50 of 11 μM for SARS-CoV-2 in Huh7.5 cells). SARS-CoV-2 PLpro-IN-7 is applicable to research related to COVID-19 .
    SARS-CoV-2 PLpro-IN-7
  • HY-181262

    SARS-CoV Virus Protease Infection
    SARS-CoV-2 PLpro-IN-4 is a SARS-CoV-2 papain-like protease (PL Pro) inhibitor with an IC50 of 0.4 μM. SARS-CoV-2 PLpro-IN-4 binds to the S3 and S4 pockets of SARS-CoV-2 PL Pro, thereby functionally inhibiting its activity. SARS-CoV-2 PLpro-IN-4 exhibits antiviral activity and can be used in research on COVID-19 .
    SARS-CoV-2 PLpro-IN-4
  • HY-179293

    SARS-CoV Virus Protease Infection
    SARS-CoV-2 PLpro-IN-3 (Compound 15) is a covalent inhibitor of the SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 25 nM. SARS-CoV-2 PLpro-IN-3 has similar inhibitory activity against SARS-CoV PLpro (IC50 = 59 nM), but shows no inhibitory effect on human ubiquitin-specific protease 7 (USP7). The EC50 of SARS-CoV-2 PLpro-IN-3 in inhibiting SARS-CoV-2 replication in cells is 96 nM, significantly reducing the viral titer and viral RNA levels. SARS-CoV-2 PLpro-IN-3 can be used for studying SARS-CoV-2 drug resistance mutations .
    SARS-CoV-2 PLpro-IN-3
  • HY-170399

    SARS-CoV Virus Protease Infection Cancer
    SARS-CoV-2 PLpro-IN-1 (Compound 85) is a non-covalent and competitive inhibitor of SARS-CoV-2 PLpro with an IC50 of 15.06 μM and a Ki of 22.93 μM. SARS-CoV-2 PLpro-IN-1 inhibits the proliferation of Vero cell with an IC50 of 7.47 μM .
    SARS-CoV-2 PLpro-IN-1
  • HY-181641

    SARS-CoV Virus Protease Infection
    SARS-CoV-2 PLpro-IN-6 is an irreversible SARS-CoV-2 papain-like protease inhibitor with an IC50 value of 0.059 μM. SARS-CoV-2 PLpro-IN-6 exhibits antiviral activity and can be used in studies related to COVID-19 .
    SARS-CoV-2 PLpro-IN-6
  • HY-172350

    SARS-CoV Virus Protease Interleukin Related Infection
    WEHI-P8 is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor with an IC50 of 12 nM and a Kd of 9.0 nM. WEHI-P8 reduces viral load, body weight loss, pulmonary inflammation, immune cell infiltration and pro-inflammatory mediator levels in SARS-CoV-2-infected mice. WEHI-P8 prevents pulmonary hemorrhage, immune cell infiltration, fibrotic remodeling and neuroinflammation, and improves cognitive function in a mouse model of post-acute sequelae of SARS-CoV-2 infection (PASC). WEHI-P8 is applicable for the research of COVID-19 and PASC .
    WEHI-P8
  • HY-159633

    SARS-CoV Infection
    PLpro-IN-5 (compound 21) is a PLPro protease inhibitor with an IC50 value of 91.14 nM. PLpro-IN-5 shows broad-spectrum antivirus, especially for SARS-CoV, MERS-CoV, SARS-CoV-2 .
    PLpro-IN-5
  • HY-157144

    SARS-CoV Infection
    SARS-CoV-2-IN-68 (compound 6C) is a covalent SARS-CoV-2 PLpro/Mpro inhibitor with potent antiviral activities. SARS-CoV-2-IN-68 binds to Zn-finger domain of PLpro .
    SARS-CoV-2-IN-68
  • HY-168259

    SARS-CoV Infection
    PLpro-IN-8 (compound 1) is a SARS-CoV papain-like protease (PLpro) inhibitor with IC50 values of 5.9 μM and 0.46 μM for SARS-CoV-2 PLpro and SARS -CoV-1 PLpro, respectively. PLpro-IN-8 inhibits Wuhan strain WK-521 of SARS-CoV-2 with an EC50 of 2.7 μM .
    PLpro-IN-8
  • HY-149256

    SARS-CoV Infection
    PLpro/RBD-IN-1 (compound 5) is a dual SARS-CoV-2 PLpro and spike protein RBD inhibitor with IC50s of 7.197 μM and 8.673 μM, respectively .
    PLpro/RBD-IN-1
  • HY-144648

    SARS-CoV Infection
    Mpro/PLpro-IN-1 (Compound 29) is a potent inhibitor of M pro/PL pro. Mpro/PLpro-IN-1 is a dual acting SARS-CoV-2 proteases inhibitor featuring micromolar inhibitory potency versus M pro (IC50 = 1.72 μM) and submicromolar potency versus PL pro (IC50 = 0.67 μM) .
    Mpro/PLpro-IN-1
  • HY-W423489

    S-Adenosyl-DL-homocysteine

    SARS-CoV Infection
    SARS-CoV-2-IN-76 (compound 1) is a nsp14-viral cap N7 methyltranferase and PLpro inhibitor of severe acute respiratory syndrome corona virus (SARS-CoV-2) .
    SARS-CoV-2-IN-76
  • HY-174402

    SARS-CoV Infection
    PLpro-IN-9 (Compound 14e) is a SARS-CoV-2 PLpro inhibitor with an IC50 of 12.0 μM and a KD of 1.86 μM. PLpro-IN-9 has low cytotoxicity but poor metabolic stability. PLpro-IN-9 can be used in the research of SARS-CoV-2 .
    PLpro-IN-9
  • HY-161365

    SARS-CoV Infection
    PLpro-IN-2 (Compound 16) is an inhibitor for SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 0.25 μM .
    PLpro-IN-2
  • HY-139892

    SARS-CoV Infection
    XR8-69 is a SARS-CoV-2 PLpro inhibitor that shows low micromolar antiviral potency in SARS-CoV-2-infected human cells.
    XR8-69
  • HY-162790

    SARS-CoV Virus Protease Infection
    SARS-CoV-2-IN-95 (Compound 10) is an inhibitor for SARS-CoV-2 PLpro with an IC50 of 0.39 μM. SARS-CoV-2-IN-95 exhibits antiviral activity in mouse SARS-CoV-2-infected model .
    SARS-CoV-2-IN-95
  • HY-150789

    SARS-CoV Infection
    SARS-CoV-2-IN-23 (compound GRL-0617) is a SARS-COV-2 papain-like protease (PLpro) inhibitor with an IC50 value of 2.3 μM .
    SARS-CoV-2-IN-23
  • HY-164868

    SARS-CoV Infection
    SARS-CoV-2-IN-106 (compound 19) is a SARS-CoV-2 papain-like protease inhibitor with the IC50 values of 0.44 μM and 0.18 μM for PLpro enzymatic and viral replication ,respectively .
    SARS-CoV-2-IN-106
  • HY-161729

    SARS-CoV Infection
    PLpro-IN-3 (compound 26R) is a potent Papain-like protease (PLpro) inhibitor with a IC50 of 1.0μM. PLpro-IN-3 exhibits antiviral activity against SARS-CoV-2 with a EC50 of 4.3 μM .
    PLpro-IN-3
  • HY-144647

    SARS-CoV Virus Protease Infection
    SP inhibitor 1 (compound 34) is a selective SARS-CoV-2 spike protein (SP) inhibitor with an IC50 of 3.26 μM, >25 μM, >25 μM for SP, M pro and PL pro protein, respectively. SP inhibitor 1 is a vitro SARS-CoV-2 replication inhibitor at non-toxic concentrations (0.3250<5.98 μM). SP inhibitor 1 shows cellular antiviral activity .
    SP inhibitor 1
  • HY-158751

    SARS-CoV Infection
    Jun9-72-2 is a papain (Plpro) inhibitor of SARS-CoV-2 with an IC50 value of 0.67 μM. Jun9-72-2 has antiviral activity .
    Jun9-72-2
  • HY-168917

    9-AMN

    SARS-CoV Virus Protease Infection
    9-Aminominocycline (9-AMN) is the inhibitor for SARS-CoV-2 papain-like protease (SARS-CoV-2 PLpro), inhibits its deubiquitination (DUB) activity and protease activity with IC50 of 4.55 µM and 4.15 µM. 9-Aminominocycline inhibits the SARS-CoV variants Delta and Omicron replication in Calu-3 cell with IC50 of 1.04 µM and 2.35 µM .
    9-Aminominocycline
  • HY-170504

    SARS-CoV Virus Protease Infection
    ZHAWOC25153 (Compound 17o) is a SARS-CoV-2 papain-like cysteine protease (PLpro) inhibitor, with an IC50 of 7 μM. ZHAWOC25153 exhibits antiviral activity and can be used in research within the field of anti-infection .
    ZHAWOC25153
  • HY-159655

    SARS-CoV Infection Inflammation/Immunology
    PLpro-IN-6 (compound 6) is a papain-like protease (PLpro) inhibitor, with an IC50 of 0.019 μM for SARS CoV2 PLpro enzyme .
    PLpro-IN-6
  • HY-155308

    SARS-CoV Infection
    SARS-CoV-2-IN-61 (compound 8i) is a SARS CoV-2 PLpro inhibitor with an IC50 of 16 µM. SARS-CoV-2-IN-61 has antiviral activities .
    SARS-CoV-2-IN-61
  • HY-149940

    SARS-CoV Infection
    SIMR3030 is a potent SARS-CoV-2 PLpro inhibitor with an IC50 value of 0.0399 µg/mL. SIMR3030 shows antiviral activity. SIMR3030 decreases SARS-CoV spike, ORF1b, IFN-α, IL-6 mRNA expression. SIMR3030 exhibits a satisfactory safety profile in mice .
    SIMR3030
  • HY-181352

    Virus Protease SARS-CoV Infection
    SB-140 is a selective, covalent PLpro inhibitor with an IC50 of ≤2.5 nM against SARS-CoV-2 PLpro. SB-140 has antiviral activity against SARS-CoV-2, MERS-CoV and SARS-CoV-1 .
    SB-140
  • HY-168584

    SARS-CoV Infection
    SARS-CoV-2-IN-102 (example 58) is a SARS-CoV papain-like protease (PLpro) inhibitor with an IC50 <100 nM .
    SARS-CoV-2-IN-102
  • HY-N0886R

    Isobarbaloin (Standard)

    Reference Standards Virus Protease SARS-CoV Infection Metabolic Disease Cancer
    Aloin B (Isobarbaloin) (Standard) is the analytical standard of Aloin B. This product is intended for research and analytical applications. Aloin B is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor with an IC50 of 16.08 μM (hydrolytic activity) and 17.51 μM (deubiquitinase activity). Aloin B is metabolized by rat intestinal flora into aloe-emodin-9-anthrone to exert laxative effects. Aloin B inhibits TPA (HY-18739)-induced ear edema, putrescine elevation, and tumor promotion in mouse skin. Aloin B can be used in research related to anti-inflammation, tumor promotion inhibition, coronavirus disease 2019 (COVID-19) and constipation .
    Aloin B (Standard)
  • HY-182894

    Virus Protease SARS-CoV Infection
    MR1-114 is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor with an IC50 of 0.037 μM. As a broad-spectrum inhibitor, MR1-114 maintains submicromolar activity against SARS-CoV-2 Delta, Omicron B.1.1.529 and Omicron BA.5 variants, with EC50 values of 0.18 μM, 0.39 μM and 0.20 μM, respectively. MR1-114 can be used for the research of coronavirus disease 2019 (SARS-CoV-2 infection) .
    MR1-114
  • HY-152589

    SARS-CoV Infection
    Antiviral agent 25 (compound 6g) is a new non-peptide analog covalent inhibitor of SARS-CoV-2 3CL pro. Antiviral agent 25 has a strong inhibitory effect on SARS-CoV-2 3CL pro and SARS-CoV-2 PL pro with IC50 values of 0.118 µM, 0.448 µM, respectively. Antiviral agent 25 has antiviral effect on SARS-CoV-2 with an EC50 value of 7.249 µM .
    Antiviral agent 25
  • HY-183746

    P-glycoprotein SARS-CoV Virus Protease Infection
    Catechin-5-O-gallate is a bioactive substance. Catechin-5-O-gallate can be isolated from bioactive Himalayan plants. Catechin-5-O-gallate is predicted to be a P-glycoprotein inhibitor, and binds to SARS-CoV-2 3CLpro, PLpro and RdRp. Catechin-5-O-gallate can be used in studies related to COVID-19 .
    Catechin-5-O-gallate
  • HY-173305

    SARS-CoV Virus Protease Infection
    Mpro/PLPro-IN-2 (Compound 22l) is a non-covalent competitive dual inhibitor of the papain-like protease and main protease of SARS-CoV-2, with a Ki of 0.2 μM for the papain-like protease and a Ki of 1.1 μM for the main protease . Mpro/PLPro-IN-2 can be used in the research field of anti-SARS-CoV-2 .
    Mpro/PLPro-IN-2
  • HY-100575R

    Acriflavinium chloride 3,6-Acridinediamine mix (Standard)

    Fluorescent Dye Reference Standards HIF/HIF Prolyl-Hydroxylase Bacterial SARS-CoV Monocarboxylate Transporter Fungal Infection Cancer
    Acriflavine (Standard) is the analytical standard of Acriflavine (HY-100575). This product is intended for research and analytical applications. Acriflavine (Acriflavinium chloride) is a fluorescent acridine dye that can be used to label nucleic acid. Acriflavine is an antiseptic agent. Acriflavine is a potent HIF-1 inhibitor that prevents the dimerization of HIF-1α and HIF-1β subunits. Acriflavine inhibits the interaction between monocarboxylate transporter 4 (MCT4) and Basigin. Acriflavine is used in cancer research, such as breast cancer, brain tumor and chronic myeloid leukemia. Acriflavine is a potent papain-like protease (PLpro) inhibitor, which inhibits SARS-CoV-2 .
    Acriflavine (Standard)
  • HY-181661

    SARS-CoV Virus Protease Infection
    YL1004 is a potent, selective and orally active noncovalent inhibitor of SARS-CoV-2 papain-like protease (PL pro). YL1004 shows an IC50 of 17.5 nM and a Ki of 2.3 nM against PL pro, with an in vitro anti-SARS-CoV-2 EC50 of 0.08 μM-1.37 μM. YL1004 suppresses the proteolytic activity of PL pro and blocks its deubiquitinating and deISGylating effects to restore host innate antiviral immune signaling. YL1004 inhibits the replication of wild-type, Delta, Omicron variants and nirmatrelvir-resistant strains of SARS-CoV-2. YL1004 can be used for the research of COVID-19 (SARS-CoV-2 infection) .
    YL1004
  • HY-182428

    SARS-CoV Infection
    UAWJ248 is a SARS-CoV-2 main protease (M pro) inhibitor with an IC50 of 0.012 μM. UAWJ248 inhibits activity via initial reversible binding followed by irreversible inactivation. UAWJ248 inhibits SARS-CoV-2 replication and can be used for the research of SARS-CoV-2 infection .
    UAWJ248

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: